Business Wire

MapleStory Expands Game Universe in Neo Part One Update With New Archer Class, Kain

Share

MapleStory, the iconic free-to-play global MMORPG from Nexon, has today launched Neo: Darkness Ascending, Part One of its summer update, the largest content update to the game in 2021. Neo Part One adds an all new area, Cernium, increases the max level to 300, and offers special limited-time events today, in addition to adding a new Nova Archer job, Kain, on June 23.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005162/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

MAPLESTORY EXPANDS GAME UNIVERSE IN NEO PART ONE UPDATE WITH NEW ARCHER CLASS, KAIN (Graphic: Business Wire)

First, a new Nova Archer job – the Darkness Chaser, Kain – joins the game on June 23. Kain is a powerful archer, fighting to recover his lost past after discovering that his organization had deceived him. Using the Whispershot, a one-handed weapon, alongside melee weapons from his Weapon Belt, Kain commands an effective and versatile weapons mastery to inflict critical hits on his enemies.

The border between two worlds has disappeared and Cernium, City of the Gods, has reappeared. New area Cernium is now available in-game and brings new challenges and quests to all players. For an added boost, a special power called Sacred Power is now available to aid in the battle against monsters inhabiting the Grandis Continent. Sacred Power is acquired by equipping Sacred Symbols, which can be enhanced to increase Sacred Power as well as main stats.

Starting today, the maximum character level is increased from 275 to 300 and the amount of EXP required to level up between levels 210-250 has been reduced. The update also includes increased EXP rewards for Arcane River quests, and modifies the character death penalty to a decreased drop rate percentage instead of overall experience lost.

Part One of the Neo Update also brings the new Neo Castle event to MapleStory. Neo Castle, an area shrouded in mystery, was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events with the following features and shops available now:

  • Neo Stone Shop: Players can exchange Neo Stones for a variety of improvements that can be used to enhance items and boost character growth
  • Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
  • Neo Core Shop: Neo Cores can be collected by battling bosses and can be used to purchase a variety of rare items
  • Neo Meso Shop: The Meso shop is stocked full of powerful items that can be purchased using Mesos

The Neo Update also includes the following updates and features:

Burning World and Tera Burning

Burning World and Tera Burning events return to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon.

The Better Maple Project brings a host of new improvements for overall improved gameplay including:

  • The V Matrix has been improved for easier use
  • Boss Battles have been improved and a new boss entry system has been added, allowing players to move to the waiting area immediately from the current channel simply by selecting the boss, difficulty and pressing “GO”
  • Skill Tooltips have been widened for better legibility and understanding of skill descriptions
  • Equipped item functionality has been improved, allowing players the ability to compare equipped items with other items linked in chat
  • The Clean Slate Scroll has been updated, and while in possession, is changed to a Pure Clean Slate Scroll to protect the item from being destroyed when it fails
  • A Notification has been added to alert players when Safeguard is automatically disabled during Star Force enhancement
  • Meso Market trades that are in progress for other characters in the same world have been updated and can be viewed in addition to canceling or receiving trades
  • The Meso Market’s daily listing limit has been increased to 20
  • Maplers can now purchase Mu Gong's Soul Shard from the Mu Lung Dojo Point Shop

To learn more about MapleStory, please visit http://maplestory.nexon.net

Social Media:TikTok/Twitter / Instagram / Twitch / Facebook / YouTube / Website

About MapleStory https://maplestory.nexon.net

MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.

About Nexon America Inc.https://www.nexon.com/

Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nexon America
Yoonmi Park
yopark@nexon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye